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We compared outcomes of 141 consecutive patients who re-
ceived allogeneic SCT between 1997 and 2004 with either MA
or NMA conditioning to treat non-Hodgkin (MA 62; NMA 
53) or Hodgkin (MA  3; NMA  23) lymphoma. NMA
patients were older [MA: 42 years (4–58); NMA: 48 years
(19–66)] and more recently transplanted [1997–2000: MA  31;
NMA  10; 2001–2004: MA  34; NMA  66]. Cord blood was
used more frequently in the NMA cohort [MA: 6 (9%); NMA:
33 (43%)]. NMA patients had more advanced disease with 57
(75%) in second or greater partial remission (PR) versus 37
(57%) MA patients. Those in complete remission comprised 12
(16%) patients in the NMA cohort and 17 (26%) in the MA
cohort. The remainder were in ﬁrst PR. Thirty patients (39%),
all NMA, had prior autologous transplants. Conditioning regi-
mens consisted of CyTBI, BuCy, or Fludarabine (75 mg/m2)
Cy(120 mg/kg) TBI 13.2Gy for MA and TBI 2.0Gy plus either
Fludarabine (200 mg/m2) Cy (50 mg/kg), Bu (8 mg/kg) Flu, or
Bu Cladrabine(50 mg/m2) for NMA. GVHD prophylaxis was
primarily cyclosporine (CSA)/methotrexate in the MA cohort
(n  59) and CSA/mycophenolate mofetil in the NMA cohort
(n  76). Results are shown in Table 1. In the evaluable
population, primary neutrophil engraftment at day 28 was not
different between the MA and NMA cohorts; however, time to
ANC 500 was signiﬁcantly shorter in the NMA population.
One year treatment related mortality (TRM) was signiﬁcantly
lower for patients in the NMA cohort but the risk of relapse at
1 year was higher. Acute GVHD grade II-IV and grade III-IV
did not differ nor was there a difference in the cumulative
incidence of chronic GVHD at 1 year. Overall survival (OS) at
1 year was lower in the MA cohort but similar by 3 years of
follow-up. Disease free survival (DFS) did not differ at 1 or 3
years. Year of transplant, recipient age, stem cell source, and
related donor were not predictive of OS or DFS. For the NMA
patients, there was a suggestion that those with low grade
lymphoma (n  21) were more likely to be alive and disease free
whereas patients with T cell (n  6) or Hodgkin lymphomas
were likely to relapse or die. Prior autologous transplant, stem
cell source, and disease status did not impact outcomes in the
NMA cohort. These results suggest that the greater TRM of a
MA regimen is balanced by a greater risk of relapse with a NMA
regimen in lymphoma patients. Further investigations to deter-
mine appropriate candidates for the NMA approach are ongoing
(Table 1).
Table 1. Results
Myeloablative
(n  65)
Non-
myeloablative
(n  76) P-value
Cumulative Incidence
of Neutrophil
Engraftment at
day 28 (95% CI)
95% (89–100) 95% (90–100) NS
Days to ANC >500/
L (range)
16 (11–28) 9 (0–28) <0.01
TRM at 1 year 40% (28–52) 17% (9–26) <0.01
Relapse at 1 year 14% (5–22) 37% (25–48) 0.02
Grade II–IV acute
GVHD
43% (30–56) 58% (45–71) NS
Grade III–IV acute
GVHD
14% (6–22) 25% (15–35) NS
Chronic GVHD at 1
year
32% (20–45) 46% (33–59) NS
Median follow-up of
Survivors
{months(range)}
33 (12–66) 24 (10–49) 0.04
Overall Survival
1 year 54% (42–62) 66% (55–76) 0.07
3 years 48% (35–60) 38% (21–55) NS
Disease Free Survival
1 year 46% (34–58) 46% (35–57) NS
3 years 41% (29–54) 25% (11–39) NS
MA: n  29; NMA: n  40
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MY-
ELOMA IN PATIENTS OVER 70 YEARS: A MATCHED COMPARISON WITH
PATIENTS UNDER 65 YEARS
Kumar, S.1, Lacy, M.1, Dispenzieri, A.1, Hayman, S.1, Hogan, W.1,
Poratta, L.1, Elliot, M.1, Ansell, S.1, Johnston, P.1, Micallef, I.1,
Inwards, D.1, Gastineau, D.1, Litzow, M.1, Gertz, M.1 Mayo Clinic,
Rochester, MN.
Background: Autologous stem cell transplantation (ASCT) pro-
longs survival in patients (pts) with multiple myeloma (MM) as
shown by randomized trials. However, most studies included
younger pts, usually 65 or less, and the outcome for older pts,
especially those over 70, is unclear. We retrospectively reviewed
our experience with ASCT for MM in pts over 70 years.Methods:
We identiﬁed 35 pts with MM who were 70 years at the time of
their ASCT. We matched them to 70 pts (two matches per pt),
based on status at transplant (primary refractory, plateau phase,
relapse off therapy, or relapse on therapy), Durie Salmon stage,
high or low labeling index, conventional cytogenetics (abnormal vs
normal), presence of circulating plasma cells at time of stem cell
collection, in that order of priority. Results: The median age of
the groups were 55.3 (range, 37.3–64.8) and 71.7 (70–75.8) years
at transplant. The median time to transplant from diagnosis was
similar (6.4 for the older pts compared to 6.9 mos for the other,
P NS). Ten of the 35 older pts received reduced dose melphalan
(140 mg/2) compared to 3 pts in the control group; P  .01. The
median follow up from transplant was 10.1 months for the older pts
compared to 18 months for the control group. The overall re-
sponse rate was similar (97.1% for the older pts compared to
95.5% for the control group). Eleven (31%) of the older pts and 17
(24%) of the control pts achieved a CR (P  NS). The post
transplant progression free survival estimate at 1 year post trans-
plant was 65.3% for the older pts compared to 66% for the control
group (P  .3). The 2-year estimated overall survival from trans-
plant was similar; 58% for the older pts compared to 67% for the
control group. The overall survival from diagnosis was similar for
the two groups (P  .6). The median number of days hospitalized
was 9 days for the older population compared to 5 days for the
control group (P .37). Four pts died within the ﬁrst one hundred
days, one among the older patient group. Conclusions: ASCT is
feasible in selected pts with MM over 70 years. It is likely that older
pts were selected based on their overall performance status, a factor
that is difﬁcult to analyze in this retrospective review. Nearly 70%
of the elderly pts received full dose melphalan for conditioning
(200 mg/m2). The toxicity of transplant and outcome appears to be
similar to the younger pts. Pts with MM should not be excluded
from ASCT solely on the basis of their age.
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PRE-TRANSPLANT POSITIVE PET/GALLIUM SCANS PREDICT POOR
OUTCOME IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)
Jabbour, E.1, Hosing, C.1, Pro, B.1, Khouri, I.1, Younes, A.1,
Champlin, R.1, Fayad, L.1 University of Texas/M. D. Anderson Cancer
Center, Houston, TX.
High dose chemotherapy followed by autologous stem cell trans-
plantion (SCT) has become the standard of care in patients (pts)
with relapsed or refractory HL. Chemosensitivity, assessed by
conventional tomography, has been correlated with better disease
free survival (DFS) and outcome. We assessed the value of func-
tional imaging (FI) in pts with HL referred to MDACC and
treated with high dose chemotherapy followed by SCT from De-
cember 1999 to May 2004. Twohundred ﬁfteen pts, male 60%,
median age 31 years, (range 10–76), with nodular sclerosis type
90%, were diagnosed at stages I (2%), II (43%), III (32%), and IV
(23%). Eighty-six percent of the pts were treated with ABVD-
based regimens, 45% received adjuvant radiation therapy. Thirty-
one percent of the pts were primary refractory. Most of the pts
(90%) were salvaged with ESHAP chemotherapy, and the prepar-
ative regimen was BEAM in 80%. At the time of salvage therapy,
B symptoms were present in 60% of the pts, extra-nodal disease
was documented in 24%, and relapse beyond 12 months of re-
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sponse occurred in 47%. Response was evaluated, before SCT, by
PET scan and Gallium scan in 68 and 147 pts, respectively.
Fifty-one percent of the pts were in complete response (CR) or
unconﬁrmed complete response (CRu), 41% were in partial re-
sponse (PR), and 7% were stable or progressive by CT scan. PET
scan and Gallium scan were positive in 25 of 68 (37%) and 43 of
147 (29%) pts, respectively. Relapses occurred in 44 of 122 (36%)
pts. FI were positive in only 5% of the pts in CR or Cru; in contrast
FI were positive in 54% of pts in PR and in almost all patients with
progressive disease. At 3 years, the cumulative probability of PFS
was 65% for pts with a negative FI versus 22% for pts with a
positive FI (P  .0001). The 3 years OS were 94% and 73% (P 
.001) for pts with positive FI and pts with negative FI, respectively.
The 3 years PFS for pts in PR with negative FI (51%) was similar
to patients in CR (71%) (P  .188) while the 3 PFS for pts in PR
with positive FI was worse (51%) (P  .0001). The 3 years OS was
similar. In a multivariate model, positive FI affected independently
the PFS and the OS. Pre-transplant functional imaging status
predicts outcome in patients with relapsed/refractory HL. Positive
pre-SCT FI confer a poor prognosis, independent of other tradi-
tional pre-salvage prognostic factors. Patients in PR with positive
FI should be offered innovative approaches other than conven-
tional ASCT.
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A 15-YEAR REVIEW OF AUTOLOGOUS STEM CELL TRANSPLANT OF
ADVANCED RELAPSED FOLLICULAR LYMPHOMA AT THE OTTAWA
HOSPITAL
Sabloff, M.1, McDiarmid, S.1, Atkins, H.1, Bence-Bruckler, I.1,
Bredeson, C.1, Hopkins, H.1, Genest, P.1, Perry, G.1, Huebsch, L.1
Ottawa Hospital, Ottawa, ON, Canada.
Introduction: Follicular lymphoma (FL) is regarded as an in-
curable disease and no single treatment has been shown to have a
signiﬁcant impact on overall survival during its relapsing/remitting
phase. Autologous stem cell transplantation has been investigated
with regard to whether such intensive treatment may have a more
signiﬁcant impact on the disease course. Methods: We completed
a retrospective review of a cohort of 139 unpurged autologous stem
cell transplants at the Ottawa Hospital for relapsed, advanced FL
over a period of 10 years with follow-up to the end of 2003. One
hundred seventeen of these transplants were for relapsed non-
transformed FL. The conditioning regimen consisted of Melpha-
lan (140 mg/m2), VP-16 (60 mg/m2), and total body irradiation
(500 or 1200 cGy). A minimum of 2.5 106 CD34 cells/Kg were
collected and infused. Results: The median age of the cohort was
48 years. The median follow-up was 5.6 years. The majority had
FL grade I and 53% were treated in ﬁrst relapse. The estimated
progression-free survival (PFS) was 47% and overall survival (OS)
was 51% at 10 years for all patients. The 5 year PFS of 58% for
patient with non-transformed FL was much better than the 27% 5
year PFS for patients with transformed FL. There was a trend
toward a better 5 year OS for the patients who underwent trans-
plantation for non-transformed FL (71% vs 61%). Relapse oc-
curred in 42 (36%) patients. Within the non-transformed group,
there were a total of 46 deaths (40%), 3 (3%) due to regimen
related toxicity and 9 (7%) due to secondary cancer. The median
survival from diagnosis was 16 years. In a multivariable Cox pro-
portional hazards model, age, a higher TBI dose, sensitivity to
salvage chemotherapy, and lower grade histology were signiﬁcant
prognostic variables. It was also noted that although the OS didn’t
signiﬁcantly differ in those who had 1, 2, or 	2 prior chemother-
apies, their PFS post transplant was signiﬁcantly better than their
respective PFS prior to transplant. Conclusions: We conclude
that unpurged autologous stem cell transplantation following high
dose chemotherapy is a safe and efﬁcacious treatment for multiply
relapsed FL. This treatment may prolong survival when used at
any stage of the disease. At the meeting, a further update of the
data will be presented with follow-up to the end of 2005, extending
the follow-up to 15 years. This will also include an analysis of their
survival after relapse post transplant.
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MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION IN POOR PROGNOSIS PATIENTS WITH ADVANCED
FOLLICULAR LYMPHOMA—EFFECTIVE THERAPY IN FIRST COMPLETE
OR PARTIAL REMISSION
Papajik, T.1, Faber, E.1, Raida, L.1, Prochazka, V.1, Vondrakova, J.1,
Rozmanova, S.1, Jarosova, M.1, Indrak, K.1 Hemato-oncology Depart-
ment, University Hospital, Olomouc, Czech Republic.
Conventional chemotherapy is not curative in patients (pts) with
generalized follicular lymphoma (FL), and most of them ultimately
die from the disease, with a median survival of 8 to 10 years. The
addition of rituximab to initial combination chemotherapy (eg,
R-CVP) prolongs duration of response, but the overall results in
high-risk prognostic group are still unsatisfactory. High-dose che-
motherapy and autologous stem cell transplantation (AT) in
younger pts with accumulation of several adverse prognostic fac-
tors can improve their outcome and prolong survival. Between
1997 and 2005, a total of 22 pts (16 women, 6 men) with poor-
prognosis FL grades I and II were intensively treated (antracycline-
based therapy) at our department. Imunochemotherapy with rit-
uximab was administrated in 11 of them. Seven pts achieved
complete remission (CR) and 15 pts partial remission (PR), mostly
with a tumor reduction greater than 75%. After BEAM condition-
ing therapy, median of 8,1  106kg (range, 2,1–20,8  106/kg)
CD34 peripheral blood stem cells were reinfused. At 100 days
following AT, 18 pts were in CR and 4 pts in PR. Three pts in PR
were treated with rituximab and all achieved CR. At the time of
diagnosis, 15 pts had bcl-2/IgH PCR-positive lymphoma cells in
samples from bone marrow (BM). Fourteen pts had no PCR-
detectable lymphoma cells in BM at 100 days after AT, 1 pt cleared
lymphoma cells from BM after rituximab therapy. Five out of 22
pts (23%) relapsed/progressed after a median time of 16 months
from AT and 3 pts died from recurrent lymphoma. Seventeen pts
are still alive in CR with median follow-up of 24 months (range
3–93 months) from AT. Estimated 7 years overall survival and
event free survival rates were 73% and 70%, respectively. Myeloa-
blative chemotherapy and autologous stem cell transplantation in
poor prognosis pts with advanced follicular lymphoma can lead to
long-lasting molecular CR. The standard administration of a front-
line immunochemotherapy with rituximab can further improve the
rate of CR and clear lymphoma cells from BM and peripheral
blood before stem cells collection. Supported by IGA NC-7490
and VVZ MSM 619 895 9205 grants.
330
A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
(autoSCT) FOLLOWED BY REDUCED INTENSITY (RI) ALLOGENEIC
TRANSPLANTATION (AlloSCT) IN CHILDREN AND ADOLESCENTS WITH
RELAPSED HODGKIN’S DISEASE (HD) AND NON-HODGKIN’S LYM-
PHOMA (NHL)
Bradley, M.B.1, Cooney, E.1, George, D.1, Garvin, J.1, Del Toro, G.1,
Bhatia, M.1, Roman, E.1, Satwani, P.1, Militano, O.1, Cheung, Y.-K.2,
Kelly, K.1, van de Ven, C.1, Schwartz, J.4, Gewanter, R.3, Martin, P.6,
Kurtzberg, J.6, Cairo, M.S.1,4,5 1. Dept of Pediatrics, Columbia Uni-
versity, NY, NY; 2. Dept. of Biostatistics, Columbia University, NY, NY;
3. Dept. of Radiation Oncology, Columbia University, NY, NY; 4.
Pathology, Columbia University, NY, NY; 5. Medicine, Columbia Uni-
versity, NY, NY; 6. Dept of Pediatrics, Duke University, Durham, NC.
AlloSCT may be beneﬁcial to patients with relapsed/refractory
HD and NHL by providing a graft versus lymphoma effect.
Carella et al (JCO 2000) and Gutman et al (BMT 2005) demon-
strated the feasibility and success of MA AutoSCT followed by RI
AlloSCT in adults with refractory lymphoma. We investigated MA
AutoSCT followed by RI AlloSCT in children with relapsed/
refractory HD/NHL. Twelve patients entered post reinduction
therapy (3CR2PR post Ifos/Carbo/VP-16, 1PR1CR post Ifos/
Vinorelbine, 1PR post Topotecan/Ifos/Carbo, 1CR post vinorel-
bine/gemcitabine, 1PR post cytarabine/VP-16/MTX, 1PR post
cytarabine/VP-16/L-asp/prednisone, 1CR post carmustine/VP-
16/cyclophosphamide). MA: Cyclophosphamide 1500 mg/m2 
4d, carmustine 100 mg/m2  3d, VP-16 800 mg/m2  3d, 
AutoSCT. CD20 patients received Rituximab (375 mg/m2/
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